A Helios & Partners Company
Label

The Beauty Repricing Is Here, and It’s a Buying Window

November 18, 2026
Helios Worldwide

The Market Just Said No

In late September, smart ring maker Oura postponed its IPO. By all operational accounts, the company was healthy: it reported strong demand for the offering, rapid top-line growth, and actual profitability. Yet prospective institutional investors reportedly balked at a target valuation of up to ~$15.6 billion—a massive step-up from its last private valuation of $11 billion.

Oura’s pause wasn’t an indictment of the business; it was a referendum on price. For the better part of a decade, beauty, personal care, and consumer wellness operated under a "growth-at-all-costs" halo, insulated by the belief that strong brand affinity and category tailwinds would indefinitely justify sky-high multiples. Public market investors just drew a hard line in the sand. They are still eager to buy category-defining wellness and beauty assets, just not when the future upside is already priced into day one.

Oura’s postponed debut marks the definitive peak for speculative multiples in the category. A broad-based repricing isn’t coming—it’s already underway, trickling down from late-stage crossover funds to private equity and early-stage venture.

From Price-to-Sales to Profit

Historically, M&A in beauty and wellness relied on a straightforward rule of thumb: price-to-sales, with roughly 4.5x trailing revenue serving as the industry benchmark for strong, growing brands.

During the zero-interest-rate era and the peak of the creator economy, that discipline evaporated. Brands routinely traded hands or raised capital at 12x to 13x sales—and occasionally higher—on the back of a celebrity founder, a viral TikTok moment, or sheer customer acquisition velocity. Those valuations were divorced from unit economics. High customer acquisition costs (CAC), bloated marketing budgets, and razor-thin or negative contribution margins were papered over by the promise of "scale later."

Now, the pendulum is swinging sharply back toward financial fundamentals:

  • Revenue multiples are compressing: Expect healthy, growing brands without massive scale to trade closer to 2x–3x sales, down roughly 30% to 50% from historical norms.
  • Profitability is the new gatekeeper: For brands with real bottom-line performance, the valuation metric itself is shifting from revenue to earnings. Acquirers and growth investors are increasingly underwriting deals at 15x–20x EBITDA.
  • Quality of earnings matters: Investors are scrutinizing repeat purchase rates, organic versus paid customer acquisition, and retail sell-through—not just top-line GMV.

For anyone writing checks, this reset isn’t a crisis; it’s a relief. Valuing consumer brands on cash flow rather than hype forces operational discipline, extends brand longevity, and creates real room for investors to generate returns without relying on a "greater fool" at the next round.

Don't Wait for the Crash

Meanwhile, traditional venture capital has largely retreated from consumer beauty and wellness. Having been burned by illiquid portfolios and overvalued 2021-era deals, many multi-stage funds are declining to write follow-on checks into brands they seeded just two or three years ago.

The consequence is predictable: we are heading into a wave of quiet closures, distressed asset sales, and "zombie" brands among Series A and seed-stage companies that built high-burn models and can no longer self-fund.

Most buyers are sitting on their hands, waiting for that distressed shakeout to peak—much like real estate investors waited on the sidelines for the bottom of 2008. Our advice: don’t wait for the wreckage.

Waiting for distress has two major flaws in consumer brands: by the time a brand is truly distressed, its inventory is stale, its best talent has left, and its brand equity with retailers and consumers has eroded. More importantly, you don’t need to wait for a crash to find fair prices, because a subset of pragmatic founders has already adjusted to reality.

Right now, there is a clear cohort of capital-efficient founders who see the writing on the wall. They aren’t clinging to 2021 pitch-deck math. They are:

  1. Self-repricing voluntarily: Coming to market at realistic 2.5x–3x revenue expectations.
  2. Prioritizing cash flow: Cutting vanity marketing spend to reach breakeven or profitability early.
  3. Seeking true partners: Looking for strategic capital to scale distribution rather than vanity unicorn status.

"Buying the dip" in beauty and wellness doesn’t mean bottom-fishing for broken companies trading at pennies on the dollar. It means backing the disciplined, profitable brands that repriced themselves before the market forced them to.

‍

Start the conversation

Define the objective. We’ll bring the right experts to the table.

1. About you
2. Context
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.